
AB Science Gets Go-Ahead for Phase 3 Study of Masitinib in ALS
According to a new announcement from AB Science, the company has received approval from several European countries to initiate a new phase 3 study to confirm the therapeutic potential of masitinib, a tyrosine kinase inhibitor, as a treatment for …